Shoba A. Navai

1.3k total citations
9 papers, 46 citations indexed

About

Shoba A. Navai is a scholar working on Oncology, Immunology and Surgery. According to data from OpenAlex, Shoba A. Navai has authored 9 papers receiving a total of 46 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 3 papers in Immunology and 2 papers in Surgery. Recurrent topics in Shoba A. Navai's work include CAR-T cell therapy research (4 papers), Immunotherapy and Immune Responses (3 papers) and Childhood Cancer Survivors' Quality of Life (2 papers). Shoba A. Navai is often cited by papers focused on CAR-T cell therapy research (4 papers), Immunotherapy and Immune Responses (3 papers) and Childhood Cancer Survivors' Quality of Life (2 papers). Shoba A. Navai collaborates with scholars based in United States. Shoba A. Navai's co-authors include Nabil Ahmed, Michael E. Scheurer, Raegan Hunt, Rajkumar Venkatramani, Heather E. Danysh, Tiffany M. Chambers, John Hicks, Saman K. Hashmi, Rachel E. Rau and M. Monica Gramatges and has published in prestigious journals such as Journal of Clinical Oncology, Biochemical Society Transactions and Pediatric Blood & Cancer.

In The Last Decade

Shoba A. Navai

5 papers receiving 45 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shoba A. Navai United States	4	28	16	13	10	7	9	46
Vít Drochýtek Czechia	4	28 1.0×	13 0.8×	14 1.1×	3 0.3×	4 0.6×	11	45
Marcin Płonowski Poland	5	22 0.8×	33 2.1×	25 1.9×	3 0.3×	7 1.0×	11	59
Arjan Lankester Netherlands	3	12 0.4×	22 1.4×	10 0.8×	9 0.9×	6 0.9×	3	48
Isaac A. Goldberg United States	6	12 0.4×	14 0.9×	5 0.4×	9 0.9×	9 1.3×	9	79
Salvatore Gattillo Italy	4	11 0.4×	15 0.9×	6 0.5×	12 1.2×	15 2.1×	5	58
Lizamarie Bachier‐Rodriguez United States	4	29 1.0×	10 0.6×	8 0.6×	11 1.1×	4 0.6×	21	59
Anupa Kudva United States	4	11 0.4×	10 0.6×	7 0.5×	8 0.8×	4 0.6×	6	34
Gerard Socié France	3	27 1.0×	37 2.3×	6 0.5×	13 1.3×	2 0.3×	3	84
Katharina L. Gössling Germany	4	11 0.4×	7 0.4×	14 1.1×	9 0.9×	21 3.0×	5	41
Chunmiao Zhang China	7	9 0.3×	21 1.3×	9 0.7×	9 0.9×	22 3.1×	12	78

Countries citing papers authored by Shoba A. Navai

Since Specialization

Citations

This map shows the geographic impact of Shoba A. Navai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shoba A. Navai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shoba A. Navai more than expected).

Fields of papers citing papers by Shoba A. Navai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shoba A. Navai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shoba A. Navai. The network helps show where Shoba A. Navai may publish in the future.

Co-authorship network of co-authors of Shoba A. Navai

This figure shows the co-authorship network connecting the top 25 collaborators of Shoba A. Navai. A scholar is included among the top collaborators of Shoba A. Navai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shoba A. Navai. Shoba A. Navai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Puri, Kriti, Luci Corrêa, Brian D. Friend, et al.. (2025). Cardiovascular Complications of Immune Effector Cell Therapies in Pediatric Hematological and Solid Tumors. Pediatric Blood & Cancer. 72(4). e31557–e31557.

2.

Stutzman, Sonja E., MinJae Lee, Avanthi Tayi Shah, et al.. (2025). Feasibility of Atezolizumab in Combination With Chemotherapy for Children With Relapsed or Refractory Solid Tumors. Pediatric Blood & Cancer. 72(12). e32046–e32046.

3.

Wang, Tao, Meng‐Fen Wu, Thomas Pfeiffer, et al.. (2024). Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors. Cytotherapy. 26(9). 1026–1032.

4.

Navai, Shoba A., Priya Mahajan, & Rajkumar Venkatramani. (2024). National virtual tumor boards to inform the management of children with rare cancers. Current Opinion in Pediatrics. 37(1). 56–58.

5.

Navai, Shoba A., et al.. (2021). Pediatric liposarcoma: A case series and literature review. Pediatric Blood & Cancer. 68(12). e29327–e29327. 3 indexed citations

6.

Hashmi, Saman K., Shoba A. Navai, Tiffany M. Chambers, et al.. (2019). Incidence and predictors of treatment‐related conjugated hyperbilirubinemia during early treatment phases for children with acute lymphoblastic leukemia. Pediatric Blood & Cancer. 67(2). e28063–e28063. 11 indexed citations

7.

Danysh, Heather E., Shoba A. Navai, Michael E. Scheurer, Raegan Hunt, & Rajkumar Venkatramani. (2019). Malignant melanoma incidence among children and adolescents in Texas and SEER 13, 1995–2013. Pediatric Blood & Cancer. 66(6). e27648–e27648. 14 indexed citations

8.

Fousek, Kristen, Junji Watanabe, Xingyue An, et al.. (2018). Targeting CD19-negative relapsed B-acute lymphoblastic leukemia using trivalent CAR T cells.. Journal of Clinical Oncology. 36(5_suppl). 121–121. 7 indexed citations

9.

Navai, Shoba A. & Nabil Ahmed. (2016). Targeting the tumour profile using broad spectrum chimaeric antigen receptor T-cells. Biochemical Society Transactions. 44(2). 391–396. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact